Back

State of the art in tailoring antithrombotics according to bleeding risk.

30 August 2016 (14:00 - 14:18)
Organised by:
Congress Presentation Part of: Tailoring antithrombotics according to bleeding risk Thrombosis and coagulation ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Felicita Andreotti

IRCCS Foundation Agostino Gemelli University Hospital, Rome (Italy)

4 More presentations in this session

Presentation thumbnail
Combining oral anticoagulants with antiplatelet therapy in patients with non-valvular atrial fibrillation: findings from the GLORIA-AF registry program
Professor M. Huisman (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Impact of previous exposure to oral anticoagulants on the risk of death or rehospitalization in patients with acute coronary syndrome - analysis according to the anticipated risk of bleeding.
Doctor C. Ruivo (Leiria, PT)
Abstract Slides Video
Presentation thumbnail
Aspirin versus no aspirin on top of vitamin K antagonists in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischaemic and bleeding events
Doctor G. Lemesle (Lille, FR)
Abstract Slides Video
Presentation thumbnail
Future direction for research in tailoring according to bleeding risk.
Professor R. De Caterina (Pisa, IT)
Slides Video

Access the full session

Session thumbnail
Tailoring antithrombotics according to bleeding risk

The Event

Event poster

ESC Congress 2016

30 August 2016 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study.
31 August 2019
thumbnail
Congress Session
Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more
28 August 2023
thumbnail
Congress Session
How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?
27 August 2023
thumbnail
Webinar
Anticoagulation challenges in older subjects with multimorbidity
25 July 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources